AR049940A1 - Uso de compuestos peptidicos para tratar tremor esencial y otros sindromes de tremor - Google Patents

Uso de compuestos peptidicos para tratar tremor esencial y otros sindromes de tremor

Info

Publication number
AR049940A1
AR049940A1 ARP050102604A ARP050102604A AR049940A1 AR 049940 A1 AR049940 A1 AR 049940A1 AR P050102604 A ARP050102604 A AR P050102604A AR P050102604 A ARP050102604 A AR P050102604A AR 049940 A1 AR049940 A1 AR 049940A1
Authority
AR
Argentina
Prior art keywords
azethyl
lower alkyl
heterocyclyl
aryl
group
Prior art date
Application number
ARP050102604A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Stoehr
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of AR049940A1 publication Critical patent/AR049940A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP050102604A 2004-06-24 2005-06-24 Uso de compuestos peptidicos para tratar tremor esencial y otros sindromes de tremor AR049940A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58208404P 2004-06-24 2004-06-24

Publications (1)

Publication Number Publication Date
AR049940A1 true AR049940A1 (es) 2006-09-13

Family

ID=34970895

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102604A AR049940A1 (es) 2004-06-24 2005-06-24 Uso de compuestos peptidicos para tratar tremor esencial y otros sindromes de tremor

Country Status (19)

Country Link
US (1) US7427601B2 (enExample)
EP (1) EP1758606A1 (enExample)
JP (1) JP5038892B2 (enExample)
KR (1) KR20070034477A (enExample)
CN (1) CN1964733B (enExample)
AR (1) AR049940A1 (enExample)
AU (1) AU2005256468B2 (enExample)
BR (1) BRPI0512622A (enExample)
CA (1) CA2566301C (enExample)
EA (1) EA013592B1 (enExample)
IL (1) IL179732A0 (enExample)
MX (1) MXPA06015010A (enExample)
MY (1) MY146509A (enExample)
NO (1) NO20070423L (enExample)
NZ (1) NZ551207A (enExample)
TW (1) TWI361693B (enExample)
UA (1) UA88166C2 (enExample)
WO (1) WO2006000397A1 (enExample)
ZA (1) ZA200609021B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1243262B1 (en) * 2001-03-20 2006-05-31 Schwarz Pharma Ag Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain
DE60100055T2 (de) * 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
WO2005053667A1 (en) * 2003-12-02 2005-06-16 Schwarz Pharma Ag Novel use of peptide compounds for treating central neuropathic pain
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
KR20070007931A (ko) * 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
WO2006021412A2 (en) * 2004-08-27 2006-03-02 Schwarz Pharma Ag Use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US7902401B2 (en) * 2006-12-14 2011-03-08 Nps Pharmaceuticals, Inc. Fluorinated compounds
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
US8735356B2 (en) 2006-06-15 2014-05-27 Ucb Pharma Gmbh Anticonvulsant combination therapy
WO2008070994A1 (en) * 2006-12-14 2008-06-19 Nps Pharmaceuticals, Inc. Use of d-serine derivatives for the treatment of anxiety disorders
US7747551B2 (en) * 2007-02-21 2010-06-29 Neurovista Corporation Reduction of classification error rates and monitoring system using an artificial class
WO2011037833A2 (en) * 2009-09-23 2011-03-31 The University Of North Carolina At Chapel Hill Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
US20110281808A1 (en) * 2010-05-14 2011-11-17 Allmax Nutrition Inc. Composition and Method for Increasing Pre Workout Thermogenics
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
JP6027539B2 (ja) 2010-12-02 2016-11-16 ウーツェーベー ファルマ ゲーエムベーハーＵｃｂ Ｐｈａｒｍａ Ｇｍｂｈ ラコサミドの１日１回投与用製剤
EP4233861A3 (en) * 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378729A (en) 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
US6589994B1 (en) 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
WO2002013766A2 (en) * 2000-08-17 2002-02-21 Teva Pharmaceutical Industries, Ltd. Valproic acid derivatives for the treatment of pain
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
EP1695703B1 (en) * 2000-08-25 2010-08-11 Research Corporation Technologies, Inc. Anticonvulsant amino acids for the treatment of obsessive-compulsive neurosis
ATE397584T1 (de) 2000-11-21 2008-06-15 Ucb Pharma Sa N-alkylierte gaba verbindungen, verfahren zu deren herstellung und deren verwendung als arzneimittel
JP2004523557A (ja) * 2001-02-23 2004-08-05 ジョンズ・ホプキンス・ユニバーシティ チック、振せん、および関連疾患の治療
EP1243262B1 (en) 2001-03-20 2006-05-31 Schwarz Pharma Ag Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain
DE60100055T2 (de) 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6828462B2 (en) * 2001-11-07 2004-12-07 Merz Pharma Gmbh & Co. Kgaa Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
EP1539145A2 (en) * 2002-09-13 2005-06-15 Eisai Co., Ltd. Method of treating tremors
US7485622B2 (en) 2002-11-18 2009-02-03 Bioprospecting Nb Inc. Paralytic peptide for use in neuromuscular therapy
US20050227961A1 (en) 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
EP1604654A1 (en) 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604656A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)

Also Published As

Publication number Publication date
CN1964733B (zh) 2012-05-23
CA2566301A1 (en) 2006-01-05
IL179732A0 (en) 2007-05-15
WO2006000397A1 (en) 2006-01-05
US20050288234A1 (en) 2005-12-29
UA88166C2 (ru) 2009-09-25
MXPA06015010A (es) 2007-03-26
JP2008503533A (ja) 2008-02-07
ZA200609021B (en) 2008-04-30
CN1964733A (zh) 2007-05-16
CA2566301C (en) 2011-06-14
NO20070423L (no) 2007-03-22
EA200700108A1 (ru) 2007-06-29
EP1758606A1 (en) 2007-03-07
MY146509A (en) 2012-08-15
EA013592B1 (ru) 2010-06-30
TWI361693B (en) 2012-04-11
NZ551207A (en) 2010-07-30
AU2005256468A1 (en) 2006-01-05
BRPI0512622A (pt) 2008-03-25
KR20070034477A (ko) 2007-03-28
US7427601B2 (en) 2008-09-23
AU2005256468B2 (en) 2010-12-09
JP5038892B2 (ja) 2012-10-03
TW200603823A (en) 2006-02-01

Similar Documents

Publication Publication Date Title
AR056467A1 (es) USO DE COMPUESTOS PEPTíDICOS PARA TRATAR DOLOR MUSCULAR
AR061475A1 (es) Compuestos peptidicos para tratar status epilepticus refractario
AR061743A1 (es) Compuestos peptidicos para el tratamiento de trastornos de hiperexcitabilidad y trastornos asociados con disfuncion del canal de hierro
AR050612A1 (es) Novedoso uso de compuestos peptidos para tratar dolor por cancer de huesos, dolor inducido por quimioterapia y nucleosidos y composicion farmaceutica
Maes et al. Two hands, one brain, and aging
AR112414A1 (es) Agonistas del receptor tipo toll 7 (tlr7) que tienen una porción benzotriazol, conjugados de estos y métodos y usos de estos
AR112689A1 (es) Agonistas del receptor tipo toll 7 (tlr7) que tienen porciones aromáticas ligadas al heteroátomo, conjugados de estos y métodos y usos de estos
PA8456901A1 (es) 2-aminopiridinas que contienen sustituyentes de anillos condensados
Leclercq et al. Genetic background of mice strongly influences treatment resistance in the 6 Hz seizure model
CY1119435T1 (el) Σκευασμα για αντισωμα εναντι- αλφα4βητα7
AR050970A1 (es) Pirimidinas 5-sustituidas con carbociclos o heterociclos inhibidoras del vih; composiciones farmaceuticas que las contienen y uso de las mismas como medicamentos.
EA201100927A1 (ru) Циклические аналоги 4-амино-4-оксобутаноил-пептидов, ингибиторы репликации вирусов
CO2018009561A2 (es) Métodos para tratar la depresión con antagonistas del receptor de orexina-2
AR040047A1 (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6
AR100770A1 (es) Uso de oxadiazoles sustituidos para combatir hongos fitopatogénicos
AR094277A1 (es) Derivados de fumarato sustituidos con deuterio
PE20071020A1 (es) Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa
BR112016012506A8 (pt) combinações farmacêuticas, seus usos, e uso de um portador de dados
DE602007010781D1 (de) N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid-derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration
AR107927A1 (es) Compuestos de pirrolidina, sal farmacéuticamente aceptable del mismo, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento
AR029185A1 (es) Derivado de naftiridina
DE60034605D1 (de) Sulfonamide und deren Derivate als Modulatoren der Endothelin-Aktivität
AR034284A1 (es) Compuestos de heterociclilalquilindol o -azaindol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la manufactura de medicamentos para tratamiento de desordenes del sistema nervioso central
CA2566301A1 (en) Novel use of peptide compounds for treating essential tremor and other tremor syndromes
MX389964B (es) Formas sólidas de un estimulador de guanilato ciclasa soluble (sgc).

Legal Events

Date Code Title Description
FA Abandonment or withdrawal